Canadian COVID-19 Vaccine DevelopmentVACCINE INDUSTRY COLLABORATING TO DEVELOP SOLUTIONS FOR COVID-19 Theralase is not the only company developing a COVID-19 vaccine in Canada. Besides the approved vaccines, the following Canadian vaccines are in the works.
IMV
Awaiting HC approval for a phase 1/2 trial of the DPX-COVID-19 vaccine
MEDICAGO
Vaccine candidate is currently in Phase 3 clinical trials. The Phase 1 results have been published on November 10th, 2020. Permission received to launch a Phase 2/3 clinical trials on November 12th, 2020.... MEDICAGO plans to submit a COVID-19 vaccine to health authorities for regulatory reviews in 2021.
SANOFI PASTEUR
Phase 2 study of adjuvanted recombinant protein COVID-19 vaccine candidate started in March 2021. A global phase 3 study could start in Q2 2021. If the vaccine meets clinical requirements on safety and efficacy, it can be expected in the fourth quarter of 2021, once approved by regulatory authorities.
Phase 1/2 clinical trial of mRNA COVID-19 vaccine started in March 2021. Interim results expected in Q3 2021
VALNEVA
As of April 21, Valneva SE initiated a pivotal Phase 3 clinical trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001...Subject to successful Phase 3 data, Valneva aims to make regulatory submissions for initial approval in the autumn of 2021.
VBI
Preclinical research was conducted through VBI’s Ottawa-based research facility in collaboration with the National Research Council of Canada (NRC), and was supported by the Government of Canada’s Innovation, Science and Economic Development (ISED) funding through the Strategic Innovation Fund (SIF). Initial data from ongoing Phase 1/2 clinical study of VBI-2902 vaccine candidate expected by the end of Q2 2021
VIDO-INTERVAC
In 2021 initiated a Phase 1 trial of COVAC-2, a vaccine formulated with Sepivac SWE™, an adjuvant developed by Seppic and the Vaccine Formulation Institute (VFI). Sepivac SWE™ is based on technology recognized for its efficacy and safety in influenza vaccines.